On August 24, 2026, Erasca, Inc. announced that the U.S. Food and Drug Administration granted Fast Track Designation to ERAS-0015 for treating metastatic pancreatic adenocarcinoma. This designation facilitates development and may expedite review through benefits such as accelerated approval, priority review, and rolling review, though it does not guarantee marketing approval or change regulatory standards. The company plans to initiate a phase 3 clinical trial in pancreatic cancer and potentially registration-enabling trials in lung cancer. Erasca, Inc. operates in the biotechnology industry, developing targeted therapies for oncology.
